Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells

Anticancer Research

Volumn 32, Issue 6, 2012, Pages 2295-2299

  Kuramitsu, Yasuhiro ^a   Wang, Yufeng ^a   Taba, Kumiko ^a   Suenaga, Shigeyuki ^a   Ryozawa, Shomei ^a   Kaino, Seiji ^a   Sakaida, Isao ^a   Nakamura, Kazuyuki ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gemcitabine (GEM); Heat shock protein 27; LC MS MS; Pancreatic cancer; Proteomics; Review; Two dimensional gel electrophoresis

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYLIDENE DERIVATIVE; GAMMA INTERFERON; GEMCITABINE; HEAT SHOCK PROTEIN 27; HEAT SHOCK TRANSCRIPTION FACTOR 1; KNK 437; TANSHINONE IIA; TRIPTOLIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CYTOTOXICITY; DIFFERENTIAL DISPLAY; DOWN REGULATION; IN VITRO STUDY; IRRADIATION; MOLECULAR MECHANICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; DRUG RESISTANCE; HUMAN; METABOLISM; PANCREAS TUMOR; PHYSIOLOGY; PROTEOMICS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; HSP27 HEAT-SHOCK PROTEINS; HUMANS; PANCREATIC NEOPLASMS; PROTEOMICS;

EID: 84864543010     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Williamson RC: Pancreatic cancer: the greatest oncological challenge. Br Med J 13: 445-446, 1988.
2. Gordis L and Gold EB: Epidemiology of pancreatic cancer. World J Surg 8: 808-821, 1984.
3. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 1-5, 1996.
4. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Taba K, Fujimoto M, Okita K, Nakamura K and Sakaida I: A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Rep 1: 429-434, 2008.
5. Kuramitsu Y, Taba K, Ryozawa S, Yoshida K, Tanaka T, Zhang X, Maehara S, Maehara Y, Sakaida I and Nakamura K: Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res 30: 3367-3372, 2010.
6. Mori-Iwamoto S, Taba K, Kuramitsu Y, Ryozawa S, Tanaka T, Maehara S, Maehara Y, Okita K, Nakamura K and Sakaida I: Interferon-γ down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Pancreas 38: 224-226, 2009.
7. Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Mori-Iwamoto S, Maehara S, Maehara Y, Sakaida I and Nakamura K: KNK-437 down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Chemotherapy 57: 12-16, 2011.
8. Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Maehara S, Maehara Y, Sakaida I and Nakamura K: Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells. Anticancer Res 30: 2539-2543, 2010.
9. Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP and Solary E: HSP27 inhibits cytochrome c-dependent activation of procaspase-9. FASEB J 13: 2061-2070, 1999.
10. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG and Fuqua SA: HSP27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat 56: 187-196, 1999.
11. Richards EH, Hickey E, Weber L and Master JR: Effect of overexpression of the small heat-shock protein HSP27 on the heat and drug sensitivities of human testis tumor cells. Cancer Res 56: 2446-2451, 1996.
12. Mymrikov EV, Seit-Nebi AS and Gusev NB: Large potentials of small heat-shock proteins. Physiol Rev 91: 1123-1159, 2011.
13. Arya R, Mallik M and Lakhotia SC: Heat-shock genes-integrating cell survival and death. J Biosci 32: 595-610, 2007.
14. Kanagasabai R, Karthikeyan K, Vedam K, Qien W, Zhu Q and Ilangovan G: Hsp27 protects adenocarcinoma cells from UV-induced apoptosis by Akt and p21-dependent pathways of survival. Mol Cancer Res 8: 1399-1412, 2010.
15. Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K and Kozawa O: TNF-α decreases HSP27 in human blood mononuclear cells: involvement of protein kinase c. Life Sci 80: 181-186, 2006.
16. Yonekura N, Yokota S, Yonekura K, Dehari H, Arata S, Kohama G and Fujii N: Interferon-γ down-regulates Hsp27 expression and suppresses the negative regulation of cell death in oral squamous cell carcinoma lines. Cell Death Differ 10: 313-322, 2003.
17. Jakubowicz-Gil J, Rzymowska J and Gawron A: Quercetin, apoptosis, heat shock. Biochem Pharmacol 64: 1591-1595, 2002.
18. Pan TL, Hung YC, Wang PW, Chen ST, Hsu TK, Sintupisut N, Cheng CS and Lyu PC: Functional proteomic and structural insights into molecular targets related to the growth inhibitory effect of tanshinone IIA on HeLa cells. Proteomics 10: 914-929, 2010.
19. Westerheide SD, Kawahara TL, Orton K and Morimoto RI: Triptolide, an inhibitor of the human heat-shock response that enhances stress-induced cell death. J Biol Chem 281: 9616-9622, 2006.
20. Shin KD, Lee MY, Shin DS, Lee S, Son KH, Koh S, Paik YK, Kwon BM and Han DC: Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. J Biol Chem 280: 41439-41448, 2005.
21. Huang Q, Ye J, Huang Q, Chen W, Wang L, Lin W, Lin J and Lin X: Heat shock protein 27 is overexpressed in tumor tissues and increased in sera of patients with gastric adenocarcinoma. Clin Chem Lab Med 48: 263-269, 2010.
22. Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE and Puri RK: Identification of potential therapeutic targets in human head and neck squamous cell carcinoma. Head Neck Oncol 1: 27-35, 2009.
23. Sakai I, Miyake H, Takenawa A and Fujisawa M: Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU Int 104: 942-946, 2009.
24. Glaessgen A, Jonmarker S, Lindberg A, Nilsson B, Lewensohn R, Ekman P, Valdman A and Egevad L: Heat-shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS 116: 888-895, 2008.
25. Song HY, Liu YK, Feng JT, Cui JF, Dai Z, Zhang LJ, Feng JX, Shen HL and Tang ZY: Proteomic analysis on metastasis-associated proteins of human hepatocellular carcinoma tissues. J Cancer Res Clin Oncol 132: 92-98, 2006.
26. Aldrian S, Trautinger F, Fröhlich I, Berger W, Micksche M and Kindas-Mügge I: Overexpression of HSP27 affects the metastatic phenotype of human melanoma cells in vitro. Cell Stress Chaperones 7: 177-185, 2002.
27. Xu L, Chen S and Bergan RC: MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 25: 2987-2998, 2006.
28. Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K and Gleave M: Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595-6602, 2004.
29. Wei L, Liu TT, Wang HH, Hong HM, Yu AL, Feng HP and Chang WW: Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB. Breast Cancer Res 13: R101, 2011.